Fennec Pharmaceuticals (TSE:FRX) Share Price Crosses Below Fifty Day Moving Average - Here's What Happened

Key Points

• Fennec Pharmaceuticals shares fell below their 50-day moving average, trading as low as C$14.47 versus the C$15.89 average. The stock’s 200-day moving average is C$13.49, with only 102 shares changing hands.
• Insiders recently reduced their holdings through sizable sales, including 106,844 shares sold by Robert Christopher Andrade and 12,000 shares sold by Pierre Sayad. Corporate insiders currently own 16.20% of the company.
• Cornerstone Capital initiated a position of 105,000 shares valued at approximately C$1.13 million, while institutional investors collectively own 15.64%. Fennec is commercializing PEDMARK/PEDMARQSI, approved to reduce chemotherapy-related hearing damage.

Fennec Pharmaceuticals Inc. (TSE:FRX - ) passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of C$15.89 and traded as low as C$14.47. Fennec Pharmaceuticals shares last traded at C$14.47, with a volume of 102 shares traded.

Fennec Pharmaceuticals Price Performance

The firm's 50-day simple moving average is C$15.89 and its two-hundred day simple moving average is C$13.49. The company has a market capitalization of C$507.42 million, a price-to-earnings ratio of -120.58 and a beta of 3.82.

Insider Transactions at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, insider Pierre Sayad sold 12,000 shares of the company's stock in a transaction dated Friday, September 4th. The shares were sold at an average price of C$17.18, for a total value of C$206,160.00. Following the sale, the insider owned 9,519 shares of the company's stock, valued at C$163,536.42. This represents a 55.76% decrease in their ownership of the stock. Also, insider Robert Christopher Andrade sold 106,844 shares of the company's stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of C$16.63, for a total value of C$1,776,815.72. Following the completion of the sale, the insider directly owned 217,675 shares in the company, valued at approximately C$3,619,935.25. The trade was a 32.92% decrease in their position. 16.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Fennec Pharmaceuticals

An institutional investor recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. acquired a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 105,000 shares of the biopharmaceutical company's stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned 0.30% of Fennec Pharmaceuticals at the end of the most recent reporting period. 15.64% of the stock is currently owned by hedge funds and other institutional investors.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.